



FOR IMMEDIATE RELEASE

CONTACT:

Kelly Sladek
SCORR Marketing
308.237.5567

Kelly@scormarketing.com

KCAS Announces Rebranding Completion and KansasBio Sponsorship

(Shawnee, Kansas; April 20, 2010) – [KCAS, LLC](#), a bioanalytical laboratory specializing in high-quality research and analytical services for pharmaceutical, biotech, animal health and medical device companies, is pleased to announce the completion of its rebranding, establishing itself as KCAS, and the honor of being in the Kansas Bioscience Organization's (KansasBio) All-Star Lineup and a founding member of the region's [National Drug Development Accelerator](#) (NDDA) team.

Twelve years after being acquired by AAIPharma, Kansas City Analytical Services has re-established itself as KCAS, LLC. With the capacity to analyze over 250,000 samples per year, KCAS provides clients with best-in-class bioanalytical services, including method development, validation and high-throughput sample analysis on biological samples for preclinical and clinical studies.

"Building on our 30-plus-year history and uncompromised attention to quality, we emphasize that our mission at KCAS is to produce reliable, high-quality results for small molecule, large molecule and biomarker analysis. We have been very pleased with the positive response from our core clients, which shows that this move is a welcome change and will be quite successful," stated President and Scientific Director of KCAS Dari Dadgar, Ph.D.

KansasBio created the NDDA for companies like KCAS in 2008. The NDDA highlights the breadth of experience and depth of knowledge in the greater Kansas City and surrounding areas. KCAS has become an integral part of drug development by providing discovery, preclinical and clinical services for the national and global biotech and pharmaceutical community. In an effort to show just how important the area is for drug development companies, KCAS has teamed up with KansasBio for the [2010 BIO International Convention](#) as an Industry Sponsor in their All-Star Lineup.

"We are enthusiastic about growing this business in a strategic and thoughtful manner. We have carved out niche markets, such as alkaline hematin, and are expanding our large molecule capabilities. Our customers should expect to see the same scientific expertise, rapid turnaround and flexibility as previous years, as well as some exciting news about us in 2010," stated Vice President of Operations at KCAS Michael Lanman.

In addition to the small molecule and large molecule bioanalytical services, KCAS has established a proprietary, validated method for quantitative measurement of menstrual blood loss ([alkaline hematin](#)) in support of women's health programs. This method is currently registered with the FDA, making KCAS a recognized leader in this field.

About KCAS, LLC

KCAS provides a full range of high-quality analytical services to pharmaceutical companies of all sizes. For more than 30 years, KCAS has provided bioanalytical services to pharmaceutical, biotech animal health and medical device companies. Delivering responsive, reliable and personalized results, KCAS boosts clients' bottom lines by enabling them to get drugs to market more quickly and effectively. For more information about KCAS, visit www.kcasbio.com.

#